Delighted to see this work on the first inhibitor/degrader of the Werner Helicase (WRN), finally published. A genetically defined synthetic lethality, to be tested in the human model system of disease. Congratulations to all from NIBR who led this program. nature.com/articles/s4158…

Very gratifying to see WRN inhibitors progressing to the clinic. Looking forward to the results

It was only in 2019 when we and others published the discovery of WRN as a target in MSI-H tumors
doi.org/10.1038/s41586…

The Cancer Dependency Map Project

Proud that our chemoproteomics survey is out @ Science Magazine . Proteome-wide profiling of >400 fragments coupled with AI/ML provides numerous starting points for drug discovery & empowers prediction of ligand behavior in native biological systems.
science.org/doi/10.1126/sc…

I spy a minor groove binder! Awesome picture BogerLab

Please join us in Montreal this June! Registration deadline is fast approaching (29-Apr). you can check out the program here: aacr.org/meeting/aacr-s…

Dr. Kevan Shokat’s groundbreaking scientific discovery has given HOPE to so many people living with cancer & their families. It was an honor having him at the White House! The #BidenCancerMoonshot is building a future where fear is replaced by hope.

Beautiful talk by Benjamin Cravatt at #AACR24 about ABPP & targeting cysteines to extend druggable space. Featuring the recently disclosed FOXA1 stereospecific covalent ligand derived from marrying diversity-oriented chemistry Stuart Schreiber with the power of chemoproteomics.

Ben Cravatt ⁦Scripps Research⁩ delivers an inspiring master class on covalent chemistry, dramatically expanding the druggable universe ⁦AACR⁩ #aacr24 👏👏👏

A very special moment at #AACR24 : Two chemistry talks in the opening plenary session!!! Showcasing the enabling power of chemistry innovation for cancer drug discovery: Carolyn Bertozzi & Benjamin Cravatt Scripps Research. Great that AACR is broadening the scope of plenaries.

So psyched for this meeting and session. Metabolic vulnerabilities, WRN allosteric inhibition, FOXA1 reprogramming, and much more to come!

Register by April 29 to get the lowest rates for the AACR Special Conference on Expanding and Translating Cancer Synthetic Vulnerabilities (June 10-13, Montreal), chaired by Stegmaier Lab, Alejandro Sweet-Cordero, MD, Michael Erb, and Kris C. Wood.
bit.ly/4cptxwB
#AACRsynth24